The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.
Prostate Cancer
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
-
Karmanos Cancer Institute, Detroit, Michigan, United States, 48201
Columbia University Irving Medical Center, New York, New York, United States, 10032
Weill Cornell Medicine, New York, New York, United States, 10065
University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States, 15232
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 99 Years
MALE
No
Weill Medical College of Cornell University,
David M Nanus, MD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University
2027-07